How are you feeling today? Keep up to date on news and stories related to healthcare here!
HOUSTON, Texas — When Tarris Marie lost her central vision to a rare, progressive eye disorder called Stargardt disease, she gained a new appreciation for her other senses and a new perspective on life. Through vivid prose, the urban crime author gives
Phase 3 results confirm the efficacy of Daiichi Sankyo and AstraZeneca’s ENHERTU in second-line metastatic gastric cancer DESTINY-Gastric04 will be unblinded at interim analysis based on the superior efficacy of ENHERTU Results will be shared with global regulatory authorities TOKYO &
NEW YORK — Employers are often overwhelmed by the daunting task of managing healthcare expenditures, and consumers are craving more transparency and clarity when it comes to understanding their policies and benefits. Ray Kober, the founder of Benefixa, a health insurance agency specializing
‒ Full year 2024 performance met or exceeded all financial guidance metrics – ‒ Q4 2024 net revenue of $731 million; GAAP net loss of $31 million; diluted loss per share of $0.10 ‒ ‒ Q4 2024 adjusted net income(1) of $40
—Portfolio helps maximize investment in LabVantage LIMS; offers tailored success plans for each customer— —Up to 75% reduction in testing efforts, 50% reduction in configuration efforts, fewer support tickets, and improved system performance— SOMERSET, N.J. — (BUSINESS WIRE) —
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union RAHWAY, N.J. — (BUSINESS WIRE) — $MRK #MRK — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, on Tuesday
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, clinical response was maintained in nearly half of patients for Psoriasis Area and
Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) CR rates were: 82.8% for patients
Surpassing $10M in revenue, Pulsetto processed nearly 40,000 orders in 2024. The company helped over 100,000 users manage stress and emotional well-being, and gained worldwide recognition as a frontrunner in longevity and health optimization. — Nearly half of the global